Literature DB >> 12720133

Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells.

Ellen D Remstein1, Curtis A Hanson, Robert A Kyle, Janice M Hodnefield, Paul J Kurtin.   

Abstract

We studied the clinical, morphologic, and immunophenotypic features of 26 Waldenstrom's macroglobulinemia (WM) cases, each with an IgM spike of >or=3.0 g/dL. The neoplastic cells were consistently composed of a spectrum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. Bone marrow (BM) involvement ranged from 10% to 90%, showed four histologic patterns (nodular [75%], interstitial [75%], paratrabecular [42%], and diffuse [4%]), two histologic subtypes (lymphoplasmacytic [87%] and lymphoplasmacytoid [13%]), and several cytologic variants (monocytoid [n = 2], signet-ring cell [n = 2], and hairy cell leukemia-like [n = 1]). By flow cytometry (FC), all cases expressed monoclonal surface immunoglobulin, CD19, and CD20. Most cases (58%) lacked expression of CD5, CD10, and CD23. However, variants such as CD5(+)CD10(-)CD23(-) (n = 3), CD5(+)CD10(-)CD23(+) (n = 1), and CD5(-)CD10(+)CD23(+/-) (n = 2) were seen. At last follow-up, 18 of 26 patients were alive (median survival, 94 months). Causes of death included WM (n = 1), large cell lymphoma (n = 1), acute myeloid leukemia (likely therapy-related [n =2]), and nonhematologic/unknown. When individual WM cases are compared, apparent morphologic diversity is suggested. However, every WM case is comprised of cells along a morphologic continuum from small lymphocytes to plasma cells, delineating a uniform, consistent pathology. As WM shows immunophenotypic heterogeneity, morphology must be the cornerstone of the diagnosis. Copyright 2003 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12720133     DOI: 10.1053/sonc.2003.50073

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  11 in total

1.  Nodal and extranodal plasmacytomas expressing immunoglobulin a: an indolent lymphoproliferative disorder with a low risk of clinical progression.

Authors:  Haipeng Shao; Liqiang Xi; Mark Raffeld; Stefania Pittaluga; Kieron Dunleavy; Wyndham H Wilson; Nelson Spector; Cristiane Milito; Jose Carlos Morais; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2010-10       Impact factor: 6.394

2.  Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review.

Authors:  Robert A Kyle; Dirk R Larson; Ellen D McPhail; Terry M Therneau; Angela Dispenzieri; Shaji Kumar; Prashant Kapoor; James R Cerhan; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2018-04-12       Impact factor: 7.616

3.  Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification.

Authors:  B Paiva; M C Montes; R García-Sanz; E M Ocio; J Alonso; N de Las Heras; F Escalante; R Cuello; A G de Coca; J Galende; J Hernández; M Sierra; A Martin; E Pardal; A Bárez; J Alonso; L Suarez; T J González-López; J J Perez; A Orfao; M-B Vidríales; J F San Miguel
Journal:  Leukemia       Date:  2013-04-22       Impact factor: 11.528

4.  CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity.

Authors:  Roxana S Dronca; Dragan Jevremovic; Curtis A Hanson; Kari G Rabe; Tait D Shanafelt; William G Morice; Timothy G Call; Neil E Kay; Charles S Collins; Susan M Schwager; Susan L Slager; Clive S Zent
Journal:  Cytometry B Clin Cytom       Date:  2010       Impact factor: 3.058

Review 5.  Novel treatment options for Waldenström macroglobulinemia.

Authors:  Houry Leblebjian; Amit Agarwal; Irene Ghobrial
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-09

Review 6.  Update on therapeutic options in Waldenström macroglobulinemia.

Authors:  Xavier Leleu; Julie Gay; Aldo M Roccaro; Anne-Sophie Moreau; Stephanie Poulain; Remy Dulery; Berenice Bro Des Champs; Daniela Robu; Irene M Ghobrial
Journal:  Eur J Haematol       Date:  2009-01       Impact factor: 2.997

7.  Waldenstrom macroglobulinemia.

Authors:  Xavier Leleu; Aldo M Roccaro; Anne-Sophie Moreau; Sophie Dupire; Daniela Robu; Julie Gay; Evdoxia Hatjiharissi; Nicholas Burwik; Irene M Ghobrial
Journal:  Cancer Lett       Date:  2008-06-13       Impact factor: 8.679

8.  MicroRNA expression in tumor cells from Waldenstrom's macroglobulinemia reflects both their normal and malignant cell counterparts.

Authors:  L S Hodge; S F Elsawa; D M Grote; T L Price-Troska; Y W Asmann; R Fonseca; M A Gertz; T E Witzig; A J Novak; S M Ansell
Journal:  Blood Cancer J       Date:  2011-06-17       Impact factor: 11.037

9.  Transgenic mouse model of IgM+ lymphoproliferative disease mimicking Waldenström macroglobulinemia.

Authors:  V S Tompkins; R Sompallae; T R Rosean; S Walsh; M Acevedo; A L Kovalchuk; S-S Han; X Jing; C Holman; J E Rehg; S Herms; J S Sunderland; H C Morse; S Janz
Journal:  Blood Cancer J       Date:  2016-11-04       Impact factor: 11.037

Review 10.  Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models.

Authors:  Siegfried Janz
Journal:  ISRN Hematol       Date:  2013-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.